Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate.

ABSTRACT:

Objective

To evaluate the long-term effects of treatments used in MS on the T-cell trafficking profile.

Methods

We enrolled 83 patients with MS under fingolimod (FTY), natalizumab (NTZ), dimethyl fumarate (DMF), or other disease-modifying treatments (DMTs). Blood was drawn before treatment onset and up to 36-48 months. The ex vivo expression of CNS-related integrins (α4β1 and α_L subunit of LFA-1) and the gut-related integrin (α4β7) was assessed using flow cytometry on CD4⁺ and CD8⁺ T cells. The adhesion profiles of CD3⁺ T cells to specific integrin ligands (vascular cell adhesion molecule-1 [VCAM-1], intercellular adhesion molecule-1 [ICAM-1], and mucosal vascular addressin cell adhesion molecule-1 [MAdCAM-1]) were measured in vitr

SUBMITTER: Mathias A 

PROVIDER: S-EPMC5639463 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature